Literature DB >> 25381128

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Bruno Paiva1, Mauricio Chandia2, Noemi Puig2, Maria-Belen Vidriales2, Jose J Perez2, Lucia Lopez-Corral2, Enrique M Ocio2, Ramon Garcia-Sanz2, Norma C Gutierrez2, Ana Jimenez-Ubieto3, Juan-José Lahuerta3, Maria-Victoria Mateos2, Jesús F San Miguel4.   

Abstract

Entities:  

Keywords:  MRD; flow cytometry; myeloma; relapse

Mesh：

Year:  2014        PMID： 25381128      PMCID： PMC4803143          DOI： 10.3324/haematol.2014.115162

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

2.  Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

Authors:  Bruno Paiva; Maria-Belén Vidriales; Jorge Cerveró; Gema Mateo; Jose J Pérez; Maria A Montalbán; Anna Sureda; Laura Montejano; Norma C Gutiérrez; Alfonso García de Coca; Natalia de Las Heras; Maria V Mateos; Maria C López-Berges; Raimundo García-Boyero; Josefina Galende; Jose Hernández; Luis Palomera; Dolores Carrera; Rafael Martínez; Javier de la Rubia; Alejandro Martín; Joan Bladé; Juan J Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2008-07-31       Impact factor: 22.113

3.  Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.

Authors:  Jean-Luc Harousseau; Meletios A Dimopoulos; Michael Wang; Alessandro Corso; Christine Chen; Michel Attal; Andrew Spencer; Zhinuan Yu; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight; Donna M Weber
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

4.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.

Authors:  Bruno Paiva; Joaquin Martinez-Lopez; Maria-Belen Vidriales; Maria-Victoria Mateos; Maria-Angeles Montalban; Elena Fernandez-Redondo; Lourdes Alonso; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; José-Garcia Laraña; Enrique Bengoechea; Alejandro Martin; Joaquin Diaz Mediavilla; Luis Palomera; Felipe de Arriba; Joan Bladé; Alberto Orfao; Juan-Jose Lahuerta; Jesus F San Miguel
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

5.  Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Authors:  Michele Cavo; Lucia Pantani; Maria Teresa Petrucci; Francesca Patriarca; Elena Zamagni; Daniela Donnarumma; Claudia Crippa; Mario Boccadoro; Giulia Perrone; Antonietta Falcone; Chiara Nozzoli; Renato Zambello; Luciano Masini; Anna Furlan; Annamaria Brioli; Daniele Derudas; Stelvio Ballanti; Maria Laura Dessanti; Valerio De Stefano; Angelo Michele Carella; Magda Marcatti; Andrea Nozza; Felicetto Ferrara; Vincenzo Callea; Catello Califano; Annalisa Pezzi; Anna Baraldi; Mariella Grasso; Pellegrino Musto; Antonio Palumbo
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

6.  The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Authors:  Ruben Niesvizky; Paul G Richardson; S Vincent Rajkumar; Morton Coleman; Laura Rosiñol; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Anthony L Boral; Dixie-Lee Esseltine; Kenneth C Anderson; Joan Bladé
Journal:  Br J Haematol       Date:  2008-07-31       Impact factor: 6.998

7.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

Authors:  Thierry Facon; Jean Yves Mary; Cyrille Hulin; Lotfi Benboubker; Michel Attal; Brigitte Pegourie; Marc Renaud; Jean Luc Harousseau; Gaëlle Guillerm; Carine Chaleteix; Mamoun Dib; Laurent Voillat; Hervé Maisonneuve; Jacques Troncy; Véronique Dorvaux; Mathieu Monconduit; Claude Martin; Philippe Casassus; Jérôme Jaubert; Henry Jardel; Chantal Doyen; Brigitte Kolb; Bruno Anglaret; Bernard Grosbois; Ibrahim Yakoub-Agha; Claire Mathiot; Hervé Avet-Loiseau
Journal:  Lancet       Date:  2007-10-06       Impact factor: 79.321

8.  VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.

Authors:  M Pineda-Roman; M Zangari; F van Rhee; E Anaissie; J Szymonifka; A Hoering; N Petty; J Crowley; J Shaughnessy; J Epstein; B Barlogie
Journal:  Leukemia       Date:  2008-04-24       Impact factor: 11.528

9.  Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Authors:  Andy C Rawstron; J Anthony Child; Ruth M de Tute; Faith E Davies; Walter M Gregory; Sue E Bell; Alexander J Szubert; Nuria Navarro-Coy; Mark T Drayson; Sylvia Feyler; Fiona M Ross; Gordon Cook; Graham H Jackson; Gareth J Morgan; Roger G Owen
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

10.  Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

Authors:  A Palumbo; F Gay; S Bringhen; A Falcone; N Pescosta; V Callea; T Caravita; F Morabito; V Magarotto; M Ruggeri; I Avonto; P Musto; N Cascavilla; B Bruno; M Boccadoro
Journal:  Ann Oncol       Date:  2008-03-06       Impact factor: 32.976
View more
  16 in total

Review 1.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Clonal evolution in myeloma: a narrow road to remission.

Authors:  Cornelius C Miething
Journal:  Haematologica       Date:  2019-07       Impact factor: 9.941

3.  A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Kenneth C Anderson; Paola Neri; Bruno Paiva; Mehmet Samur; Meletios Dimopoulos; Margarita Kulakova; Annette Lam; Mahmoud Hashim; Jianming He; Bart Heeg; Jon Ukropec; Jessica Vermeulen; Sarah Cote; Nizar Bahlis
Journal:  Blood Adv       Date:  2020-12-08

4.  Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.

Authors:  Chutima Kunacheewa; Hans C Lee; Krina Patel; Sheeba Thomas; Behrang Amini; Samer Srour; Qaiser Bashir; Yago Nieto; Muzzaffar H Qazilbash; Donna M Weber; Lei Feng; Robert Z Orlowski; Pei Lin; Elisabet E Manasanch
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-01-15

Review 5.  Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-07       Impact factor: 10.047

Review 6.  Myeloma today: Disease definitions and treatment advances.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

Review 7.  BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.

Authors:  Sarah A Holstein; Hervé Avet-Loiseau; Theresa Hahn; Christine M Ho; Jens G Lohr; Nikhil C Munshi; Bruno Paiva; Marcelo C Pasquini; Joseph D Tario; Saad Z Usmani; Paul K Wallace; Katja Weisel; Philip L McCarthy
Journal:  Biol Blood Marrow Transplant       Date:  2017-12-11       Impact factor: 5.742

8.  Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

Authors:  Juan-Jose Lahuerta; Bruno Paiva; Maria-Belen Vidriales; Lourdes Cordón; Maria-Teresa Cedena; Noemi Puig; Joaquin Martinez-Lopez; Laura Rosiñol; Norma C Gutierrez; María-Luisa Martín-Ramos; Albert Oriol; Ana-Isabel Teruel; María-Asunción Echeveste; Raquel de Paz; Felipe de Arriba; Miguel T Hernandez; Luis Palomera; Rafael Martinez; Alejandro Martin; Adrian Alegre; Javier De la Rubia; Alberto Orfao; María-Victoria Mateos; Joan Blade; Jesus F San-Miguel
Journal:  J Clin Oncol       Date:  2017-05-12       Impact factor: 44.544

Review 9.  Deep Response in Multiple Myeloma: A Critical Review.

Authors:  Mariateresa Fulciniti; Nikhil C Munshi; Joaquin Martinez-Lopez
Journal:  Biomed Res Int       Date:  2015-12-10       Impact factor: 3.411

10.  Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.

Authors:  Iole Cordone; Francesco Marchesi; Serena Masi; Valentina Summa; Francesco Pisani; Roberta Merola; Giovanni Cigliana; Giulia Orlandi; Svitlana Gumenyuk; Francesca Palombi; Atelda Romano; Antonio Spadea; Daniela Renzi; Elena Papa; Marco Canfora; Laura Conti; Maria Concetta Petti; Andrea Mengarelli
Journal:  J Exp Clin Cancer Res       Date:  2016-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.